View Financial HealthHypha Labs 配当と自社株買い配当金 基準チェック /06Hypha Labs配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095お知らせ • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 19Hypha Labs, Inc. Announces Completion of Phase 1 of Its Facility and Arrival of V5 Working MicroPearls(TM) PrototypesHypha Labs, Inc. announced it has completed Phase 1 of construction and design for its Research and Production facility in Las Vegas, Nevada as well as the arrival of its V5 MicroPearls prototype. Completion of Phase 1 at the facility is significant for a multitude of reasons, not least of which is it maintains the Company's anticipated timeline to begin roll-out of product sales in the fourth quarter of 2025. Secondly, the new facility allows the Company to expand and build upon its groundbreaking research which gives individuals the power to grow a broad array of functional mushrooms from the comfort and privacy of home in a predictable eight-day cycle. The advancements at the facility and in the V5 MicroPearls™ are significant: Facility Improvements and Additions: A new sterile clean room in the Las Vegas lab to accelerate its genetic experimentation work at Hyphalabs; Brand new mixing lab/kitchen for larger scale inventory management and personal; Newly upgraded data networks and communication equipment for the lab and offices, which allowed for more applied analysis and increases the efficacy of its Artificial Intelligence (AI) systems; Conference room upgrades to host meetings and large data screens for information sharing or other collaborative efforts; Prototyping equipment now online and built-out in its mechanical/electronic lab. This makes far more agile in its modification and enhancement efforts. The Arrival of Version 5 MicroPearls™ Mushroom Accelerator Prototypes: A new fleet of Version 5 MicroPearls™ prototypes has been delivered. V5 brings with it fully operational cloud-controlled microcontroller management in each bioreactor. This allows for consistent environmental profile control, motor controls, aeration controls, and more, all of which are now fully controlled and automated. The result is a more precise mushroom ingredient harvest for the home or Commercial operator. New Test Plans: New test plans will now be executed at a much higher rate, with more strains tested both at its internal Las Vegas facility and, thanks to its new video/data network, in collaboration with outside consultants.お知らせ • Jun 25Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium ProductionHypha Labs, Inc. announced the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Tradark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin. Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms as well. The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry.お知らせ • May 23Hypha Labs, Inc. Announces New Patent FilingHypha Labs, Inc. announced the initiation of a patent portfolio. This portfolio, spearheaded by an initial filing with the United States Patent and Trademark Office (USPTO) in March 2024, encompasses a series of inventive methods and devices designed to revolutionize the extraction of active components from mycelium, including psilocybin. These active components include psychedelic, functional and medicinal ingredients. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms. The pending patents cover the processing of mycelium, which is the vegetative part of fungi consisting of a network of thread-like hyphae, which holds immense potential in various industries including pharmaceuticals, nutraceuticals, and biotechnology. However, traditional methods of mycelium processing have often been hindered by lengthy cultivation periods and the requirement of growing mushrooms in soil over extended periods. Recognizing the need for innovation in this space, Hypha Labs, Inc. has developed pioneering techniques that bypass these limitations, offering a more efficient and sustainable approach to mycelium processing, including the growth and extraction of active psilocybin. At the heart of this patent portfolio lies a series of new and novel devices meticulously designed to organically extract desirable components from mycelium without the protracted timeline associated with traditional methods. Unlike conventional processes that necessitate the cultivation of mushrooms in soil over many months, proprietary technologies streamline the extraction process, enabling swift and efficient harvesting of mycelium's active constituents. In addition, the pending patents encompass a diverse range of devices, from large-scale industrial equipment to consumer-friendly appliances, all designed to facilitate the organic processing of mycelium with utmost efficiency and convenience. This includes devices for commercial production facilities and small table-top appliances for in-home consumer use. The devices covered by the pending patents will be for businesses and consumers alike for harnessing the full potential of mycelium and its components with ease. The significance of patents in this emerging field cannot be overstated. Patents play a crucial role in driving innovation and investment in scientific devices related to mycological sciences. They provide legal protection for groundbreaking technologies, incentivize collaboration, and facilitate the commercialization of novel solutions.お知らせ • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 30Hypha Labs, Inc. Appoints Craig Ellins as Chief Science OfficerHypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Sciences. His expertise in identifying and capitalizing on early-stage opportunities in new markets guides strategic direction. He is especially knowledgeable about the cannabis industry, which he psilocybin space is going to mirror.お知らせ • Aug 17Digipath, Inc. announced delayed 10-Q filingOn 08/15/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Digipath, Inc. announced delayed 10-Q filingOn 05/16/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 31Digipath, Inc. announced delayed annual 10-K filingOn 12/30/2022, Digipath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 01DigiPath, Inc. announced delayed annual 10-K filingOn 12/30/2020, DigiPath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jul 07DigiPath, Inc. Announces Resignation of Kyle Remenda as Chief Executive OfficerOn July 1, 2020 the Digipath, Inc. entered into a Separation and Release Agreement with Kyle Remenda, pursuant to which Mr. Remenda resigned from all of his positions with the Company and its subsidiaries, including his position as Chief Executive Officer of the Company.決済の安定と成長配当データの取得安定した配当: FUNIの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: FUNIの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Hypha Labs 配当利回り対市場FUNI 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (FUNI)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Consumer Durables)1.8%アナリスト予想 (FUNI) (最長3年)n/a注目すべき配当: FUNIは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: FUNIは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: FUNIの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: FUNIが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 19:43終値2026/05/22 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hypha Labs, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 17Hypha Labs, Inc. Auditor Raises 'Going Concern' DoubtHypha Labs, Inc. filed its 10-K on Jan 15, 2026 for the period ending Sep 30, 2025. In this report its auditor, Fruci & Associates II, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Dec 31Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/30/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 07Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million.Hypha Labs, Inc. has completed a Composite Units Offering in the amount of $10.5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 50,000,000 Price\Range: $0.21 Discount Per Security: $0.0095
お知らせ • Aug 15Hypha Labs, Inc. announced delayed 10-Q filingOn 08/14/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2025, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 01Hypha Labs, Inc. announced delayed annual 10-K filingOn 12/31/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 19Hypha Labs, Inc. Announces Completion of Phase 1 of Its Facility and Arrival of V5 Working MicroPearls(TM) PrototypesHypha Labs, Inc. announced it has completed Phase 1 of construction and design for its Research and Production facility in Las Vegas, Nevada as well as the arrival of its V5 MicroPearls prototype. Completion of Phase 1 at the facility is significant for a multitude of reasons, not least of which is it maintains the Company's anticipated timeline to begin roll-out of product sales in the fourth quarter of 2025. Secondly, the new facility allows the Company to expand and build upon its groundbreaking research which gives individuals the power to grow a broad array of functional mushrooms from the comfort and privacy of home in a predictable eight-day cycle. The advancements at the facility and in the V5 MicroPearls™ are significant: Facility Improvements and Additions: A new sterile clean room in the Las Vegas lab to accelerate its genetic experimentation work at Hyphalabs; Brand new mixing lab/kitchen for larger scale inventory management and personal; Newly upgraded data networks and communication equipment for the lab and offices, which allowed for more applied analysis and increases the efficacy of its Artificial Intelligence (AI) systems; Conference room upgrades to host meetings and large data screens for information sharing or other collaborative efforts; Prototyping equipment now online and built-out in its mechanical/electronic lab. This makes far more agile in its modification and enhancement efforts. The Arrival of Version 5 MicroPearls™ Mushroom Accelerator Prototypes: A new fleet of Version 5 MicroPearls™ prototypes has been delivered. V5 brings with it fully operational cloud-controlled microcontroller management in each bioreactor. This allows for consistent environmental profile control, motor controls, aeration controls, and more, all of which are now fully controlled and automated. The result is a more precise mushroom ingredient harvest for the home or Commercial operator. New Test Plans: New test plans will now be executed at a much higher rate, with more strains tested both at its internal Las Vegas facility and, thanks to its new video/data network, in collaboration with outside consultants.
お知らせ • Jun 25Hypha Labs, Inc. Reveals New Patent Applications for Novel Artificial Intelligence (A.I.) Driven In-Home Mycelium ProductionHypha Labs, Inc. announced the addition of significant mycological innovations to its current patent portfolio. The expanded patent portfolio now includes several filings with the United States Patent and Tradark Office (USPTO) that seek to protect a series of novel methods and devices designed to revolutionize the extraction of active components from mycelium. These active components include psychedelic, functional and medicinal ingredients such as psilocybin. Hypha Laboratories is intent on bringing the first fully functional in-home device that will allow a consumer to produce their own mushroom-based ingredients in a grow cycle of less than ten days and with greater potency precision than commonly sold mushrooms and mushroom ingredients. These home grown functional mushroom ingredients would be produced at a fraction of current market prices and in the privacy of a residence using the Company's patent pending elegant bioreactor instead of less desirable substrates such as animal waste. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms as well. The pending patents seek to protect the use of sophisticated machine learning algorithms to process mycelium, the vegetative part of fungi composed of an intricate network of hyphae. The Company believes that this has tremendous potential across various sectors including pharmaceuticals, nutraceuticals, and biotechnology. Traditionally, mycelium processing to produce psilocybin has faced challenges due to prolonged cultivation times and the necessity of soil-based mushroom growth over extended durations. To address these issues, Hypha Labs has introduced Artificial Intelligence (AI) with novel machine learning methods that overcome these barriers, providing a more efficient and sustainable way to process mycelium for cultivating, producing and extracting active psilocybin. The integration of advanced machine learning offers significant advantages, including optimized growth conditions, accelerated processing times, enhanced yield predictability, and reduced resource consumption, thus revolutionizing the mycelium industry.
お知らせ • May 23Hypha Labs, Inc. Announces New Patent FilingHypha Labs, Inc. announced the initiation of a patent portfolio. This portfolio, spearheaded by an initial filing with the United States Patent and Trademark Office (USPTO) in March 2024, encompasses a series of inventive methods and devices designed to revolutionize the extraction of active components from mycelium, including psilocybin. These active components include psychedelic, functional and medicinal ingredients. In 2022, the U.S. market for functional and psychedelic mushrooms reached a valuation of USD 3.6 billion, with anticipated growth at a CAGR of 12.1% from 2023 to 2030. This upward trajectory aligns with the increasing momentum in the United States toward the decriminalization of not only psychedelic mushrooms, but the rapid growth and benefits of functional mushrooms. The pending patents cover the processing of mycelium, which is the vegetative part of fungi consisting of a network of thread-like hyphae, which holds immense potential in various industries including pharmaceuticals, nutraceuticals, and biotechnology. However, traditional methods of mycelium processing have often been hindered by lengthy cultivation periods and the requirement of growing mushrooms in soil over extended periods. Recognizing the need for innovation in this space, Hypha Labs, Inc. has developed pioneering techniques that bypass these limitations, offering a more efficient and sustainable approach to mycelium processing, including the growth and extraction of active psilocybin. At the heart of this patent portfolio lies a series of new and novel devices meticulously designed to organically extract desirable components from mycelium without the protracted timeline associated with traditional methods. Unlike conventional processes that necessitate the cultivation of mushrooms in soil over many months, proprietary technologies streamline the extraction process, enabling swift and efficient harvesting of mycelium's active constituents. In addition, the pending patents encompass a diverse range of devices, from large-scale industrial equipment to consumer-friendly appliances, all designed to facilitate the organic processing of mycelium with utmost efficiency and convenience. This includes devices for commercial production facilities and small table-top appliances for in-home consumer use. The devices covered by the pending patents will be for businesses and consumers alike for harnessing the full potential of mycelium and its components with ease. The significance of patents in this emerging field cannot be overstated. Patents play a crucial role in driving innovation and investment in scientific devices related to mycological sciences. They provide legal protection for groundbreaking technologies, incentivize collaboration, and facilitate the commercialization of novel solutions.
お知らせ • May 17Hypha Labs, Inc. announced delayed 10-Q filingOn 05/15/2024, Hypha Labs, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 30Hypha Labs, Inc. Appoints Craig Ellins as Chief Science OfficerHypha Labs, Inc. has announced that it has made Craig Ellins its Chief Science Officer. Craig Ellins is a visionary in emerging technologies and industries, having founded and led companies like One World Pharma and GB Sciences. His expertise in identifying and capitalizing on early-stage opportunities in new markets guides strategic direction. He is especially knowledgeable about the cannabis industry, which he psilocybin space is going to mirror.
お知らせ • Aug 17Digipath, Inc. announced delayed 10-Q filingOn 08/15/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Digipath, Inc. announced delayed 10-Q filingOn 05/16/2023, Digipath, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 31Digipath, Inc. announced delayed annual 10-K filingOn 12/30/2022, Digipath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 01DigiPath, Inc. announced delayed annual 10-K filingOn 12/30/2020, DigiPath, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jul 07DigiPath, Inc. Announces Resignation of Kyle Remenda as Chief Executive OfficerOn July 1, 2020 the Digipath, Inc. entered into a Separation and Release Agreement with Kyle Remenda, pursuant to which Mr. Remenda resigned from all of his positions with the Company and its subsidiaries, including his position as Chief Executive Officer of the Company.